Earnings Preview: Sepracor

Sepracor (SEPR) is expected to report Q3 earnings before market open Tuesday, Oct. 28, with a conference call scheduled for 8:30 am.

Guidance

Analysts are looking for a profit of 15c on revenue of $292M. The consensus range for EPS is wide, (6c) to 37c, with a revenue range of $276M to $306M, according to First Call. For Q2 the company reported EPS 6c vs. consensus 23c, and Q2 revenue $294M vs. consensus $304M.

Analyst Views

Positive catalysts this quarter could come from sales growth in Brovana, a COPD treatment, and the company's new nasal spray, Omnaris. Negative drivers for this quarter's results might be declining sales of Lunesta and pressure on sales of Xopenex.

On October 9, Susquehanna upgraded Sepracor to Neutral from Negative based on valuation. On October 7, J.P. Morgan initiated Sepracor with a Neutral rating.